We wish to inform you that the subscription period for new shares in Lytix Biopharma has opened, with gross proceeds of NOK 50-100 million. The proceeds will be used to fund further clinical development of its lead product candidate, LTX-315, currently in Phase I/II combination trials with startup in 2016.

Subscription period: 19 November 2015 until 10 December 2015 at 16:30 (CET)
Subscription price:   Will be determined through book building
Conditional grant:    Around 11 December 2015
Settlement:             Around 7 January 2016

Please contact Arctic Securities (manager and financial adviser for the share issue) for more information: ivar.landgraff@arctic.com

Read article in Finansavisen about the share issue (only in Norwegian)